Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single-arm, Multicenter Phase 4 Study to Evaluate Safety and Tolerability of Romosozumab (EVENITY® ) in Postmenopausal Women in India With Osteoporosis and a High Risk of Fracture.

NCT06079476 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT06079476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06079476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single-arm, Multicenter Phase 4 Study to Evaluate Safety and Tolerability of Romosozumab (EVENITY® ) in Postmenopausal Women in India With Osteoporosis and a High Risk of Fracture.
Lead sponsor
Amgen
Phase
Phase 4
Overall status
Completed
Start date
October 30, 2023
Completion date
October 18, 2025
Enrollment
100 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis